Bionik Laboratories (BNKL) 10-Q 14 Nov 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	0001508381
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	BNKL
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,970,595

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Sep. 30, 2019	Mar. 31, 2019
Current
Cash and cash equivalents	$ 4,674,868	$ 446,779
Accounts receivable, net of allowance for doubtful accounts of $Nil (March 31, 2019 - $Nil)	481,345	1,523,193
Prepaid expenses and other receivables (Note 5)	2,192,177	1,355,032
Inventories (Note 6)	1,037,058	405,682
Due from related parties (Note 9(a))	18,932	18,585
Total Current Assets	8,404,380	3,749,271
Equipment (Note 7)	232,640	192,528
Technology and other assets (Note 4)	4,289,094	4,427,722
Goodwill	22,308,275	22,308,275
Total Assets	35,234,389	30,677,796
Current
Accounts Payable (Notes 9(b))	1,434,167	1,148,852
Accrued liabilities (Note 8 and 9(b))	1,164,998	1,653,233
Convertible Loans (Note 8(a))	70,117	0
Deferred revenue - Contract Liabilities	590,599	467,778
Total Current Liabilities	3,259,881	3,269,863
Shareholders' Equity
Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2019 - 1)
Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2019 - 500,000,000); Issued and outstanding 4,970,595 and 156,239 Exchangeable Shares (March 31, 2019 -3,661,838 and 196,799 Exchangeable Shares)	5,126	3,858
Additional paid in capital	83,787,934	73,719,299
Deficit	(51,860,701)	(46,357,373)
Accumulated other comprehensive income	42,149	42,149
Total Shareholders' Equity	31,974,508	27,407,933
Total Liabilities and Shareholders' Equity	$ 35,234,389	$ 30,677,796

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2019	Mar. 31, 2019
Allowance for Doubtful Accounts Receivable, Current	$ 0	$ 0
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	4,970,595	3,661,838
Common Stock, Shares, Outstanding	4,970,595	3,661,838
Common Stock, Other Shares, Issued	156,239	196,799
Common Stock, Other Shares, Outstanding	156,239	196,799
Special Voting [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss)
Sales	$ 281,691	$ 547,085	$ 1,072,070	$ 1,048,418
Cost of Sales	83,207	384,073	419,292	637,236
Gross Margin	198,484	163,012	652,778	411,182
Operating expenses
Sales and marketing	584,775	427,325	1,168,507	969,984
Research and development	886,060	679,049	1,702,583	1,355,792
General and administrative	1,199,938	931,477	2,041,631	1,910,956
Share-based compensation expense (Note 11)	638,219	439,328	925,976	1,034,740
Amortization (Note 4)	69,314	69,315	138,628	140,368
Depreciation (Note 7)	27,059	16,626	51,029	34,221
Total operating expenses	3,405,365	2,563,120	6,028,354	5,446,061
Other (income) expenses
Accretion expense	0	1,970,167	0	2,104,418
Fair Value Adjustment	0	(382,010)	0	(337,923)
Gain/Loss on mark to market re-evaluation	0	0	0	(2,048,697)
Other expense	170,739	22,712	185,035	60,132
Foreign exchange	5,064	(27,872)	(57,283)	(69,006)
Total other expenses (income)	175,803	1,582,997	127,752	(291,076)
Net (loss) and comprehensive (loss) for the period	$ (3,382,684)	$ (3,983,105)	$ (5,503,328)	$ (4,743,803)
Loss per share - basic and diluted	$ (0.87)	$ (1.62)	$ (1.42)	$ (2.02)
Weighted average number of shares outstanding - basic and diluted	3,872,428	2,459,169	3,865,573	2,351,587

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity - USD ($)	Special Voting [Member]Convertible Debt One [Member]	Special Voting [Member]Convertible Debt Two [Member]	Special Voting [Member]European Promissory notes tranche Three [Member]	Special Voting [Member]	Common Shares [Member]Convertible Debt One [Member]	Common Shares [Member]Convertible Debt Two [Member]	Common Shares [Member]European Promissory notes tranche Three [Member]	Common Shares [Member]	Additional Paid in Capital [Member]Convertible Debt One [Member]	Additional Paid in Capital [Member]Convertible Debt Two [Member]	Additional Paid in Capital [Member]European Promissory notes tranche Three [Member]	Additional Paid in Capital [Member]	Deficit [Member]Convertible Debt One [Member]	Deficit [Member]Convertible Debt Two [Member]	Deficit [Member]European Promissory notes tranche Three [Member]	Deficit [Member]	Comprehensive Income [Member]Convertible Debt One [Member]	Comprehensive Income [Member]Convertible Debt Two [Member]	Comprehensive Income [Member]European Promissory notes tranche Three [Member]	Comprehensive Income [Member]	Convertible Debt One [Member]	Convertible Debt Two [Member]	European Promissory notes tranche Three [Member]	Total
Opening Balance at Mar. 31, 2018				$ 0				$ 1,664				$ 56,195,541				$ (35,776,340)				$ 42,149				$ 20,463,014
Opening Balance (in shares) at Mar. 31, 2018				1				1,664,002
Share compensation expense				$ 0				$ 0				1,034,740				0				0				1,034,740
Share compensation expense (in shares)								0
Fair value of Anti-dilution feature				0				$ 0				1,766,495				0				0				1,766,495
Loss on warrant down round feature				0				0				6,284				(6,284)				0				0
Conversion of European promissory notes	$ 0		$ 0		$ 683		$ 264		$ 4,732,170		$ 2,470,358		$ 0		$ 0		$ 0		$ 0		$ 4,732,853		$ 2,470,622
Conversion of European Promissory notes (in shares)					683,395		263,639
Stock option and warrant reclassification				0				0				1,173,534				0				0				1,173,534
Net loss for the year				0				0				0				(4,743,803)				0				(4,743,803)
Closing Balance at Sep. 30, 2018				$ 0				$ 2,611				67,379,122				(40,526,427)				42,149				26,897,455
Closing Balance (in shares) at Sep. 30, 2018				1				2,611,036
Opening Balance at Mar. 31, 2018				$ 0				$ 1,664				56,195,541				(35,776,340)				42,149				20,463,014
Opening Balance (in shares) at Mar. 31, 2018				1				1,664,002
Closing Balance at Mar. 31, 2019				$ 0				$ 3,858				73,719,299				(46,357,373)				42,149				27,407,933
Closing Balance (in shares) at Mar. 31, 2019				1				3,858,637
Opening Balance at Sep. 30, 2018				$ 0				$ 2,611				67,379,122				(40,526,427)				42,149				26,897,455
Opening Balance (in shares) at Sep. 30, 2018				1				2,611,036
Share compensation expense				$ 0				$ 0				312,659				0				0				312,659
Share compensation expense (in shares)								0
Loss on warrant down round feature				0				$ 0				18,148				(18,148)				0				0
Conversion of European promissory notes		$ 0				$ 1,247				$ 6,009,370				$ 0				$ 0				$ 6,010,617
Conversion of European Promissory notes (in shares)						1,247,099
Net loss for the year				0				0				0				(5,812,798)				0				(5,812,798)
Adjustment due to 1:150 share consolidation round-up				0				$ 0				0				0				0				0
Adjustment due to 1:150 share consolidation round-up (in shares)								502
Closing Balance at Mar. 31, 2019				$ 0				$ 3,858				73,719,299				(46,357,373)				42,149				27,407,933
Closing Balance (in shares) at Mar. 31, 2019				1				3,858,637
Share compensation expense				$ 0				$ 0				925,976				0				0				925,976
Share compensation expense (in shares)								0
Conversion of European promissory notes				0				$ 1,268				9,142,659				0				0				9,143,927
Conversion of European Promissory notes (in shares)								1,268,191
Stock option and warrant reclassification				0
Net loss for the year				0				$ 0				0				(5,503,328)				0				(5,503,328)
Closing Balance at Sep. 30, 2019				$ 0				$ 5,126				$ 83,787,934				$ (51,860,701)				$ 42,149				$ 31,974,508
Closing Balance (in shares) at Sep. 30, 2019				1				5,126,828

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities
Net loss for the period	$ (5,503,328)	$ (4,743,803)
Adjustment for items not affecting cash
Depreciation	51,029	34,221
Amortization	138,628	140,368
Interest expense	167,877	57,716
Share based compensation expense	925,976	1,034,740
Accretion expense	0	2,104,418
Fair Value Adjustment	0	(337,923)
Gain/Loss on mark to market re-evaluation	0	(2,048,697)
Allowance for doubtful accounts	0	(1,995)
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(4,219,818)	(3,760,955)
Changes in non-cash working capital items
Accounts receivable	1,041,848	(303,033)
Prepaid expenses and other receivables	(837,145)	(417,524)
Due from related parties	(347)	(16)
Inventories	(631,376)	44,817
Accounts payable	285,315	181,765
Accrued liabilities	(512,068)	(567,320)
Customer advances	0	(800)
Deferred revenue	122,821	11,494
Net cash (used in) operating activities	(4,750,770)	(4,811,572)
Investing activities
Acquisition of equipment	(91,141)	(13,640)
Net cash (used in) investing activities	(91,141)	(13,640)
Financing activities
Proceeds from convertible loans	9,070,000	4,676,633
Repayment of Demand notes principal	0	(50,000)
Repayment of Demand notes interest	0	(2,975)
Proceeds from short term loan	500,000	0
Repayment of short term loan	(500,000)	0
Net cash provided by financing activities	9,070,000	4,623,658
Net increase (decrease) in cash and cash equivalents for the period	4,228,089	(201,554)
Cash and cash equivalents, beginning of period	446,779	507,311
Cash and cash equivalents, end of period	$ 4,674,868	$ 305,757

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN	6 Months Ended
	Sep. 30, 2019
NATURE OF OPERATIONS AND GOING CONCERN
NATURE OF OPERATIONS AND GOING CONCERN	1. NATURE OF OPERATIONS AND GOING CONCERN The Company and its Operations Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock-split of the common and exchangeable shares. On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”) and Bionik Canada issued 333,334 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition, the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10). On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergerco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 157,667 shares of the Company’s common stock (Note 4). On November 6, 2017, the Company approved the authorization of a common share capital share increase to 250,000,000 from 150,000,000 and on June 12, 2018, the Company approved the authorization of a common share increase to 500,000,000 from 250,000,000. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Inc., Bionik Acquisition Inc. and Bionik Canada. The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA 02472. Going Concern As at September 30, 2019, the Company had a working capital of $5,144,499 (March 31, 2019 – $479,408) and an accumulated deficit of $(51,860,701) (March 31, 2019 – $(46,357,373) and the Company incurred comprehensive loss of $(5,503,328) for the six month period ended September 30, 2019 (September 30, 2018 – $(4,743,803)). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects to raise additional funds to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these condensed consolidated financial statements.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Sep. 30, 2019
BASIS OF PRESENTATION
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION During the 2019 fiscal year, holders of the common stock and exchangeable shares of the Company approved, through a majority shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Bionik’s common stock and exchangeable shares at a ratio up to one-to-one hundred and fifty. On October 29, 2018, the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. All owners of record on October 29, 2018 received one issued and outstanding share of Bionik common stock or exchangeable share in exchange for one hundred and fifty issued and outstanding shares of Bionik common stock or Bionik exchangeable stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-one hundred and fifty reverse split were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Bionik common stock, which remains at $0.001. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements and the accompanying Notes contained in this Quarterly Report on Form 10‑Q have been restated to give retrospective presentation for the reverse stock split.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Sep. 30, 2019
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10‑K for the year ended March 31, 2019. The interim disclosures generally do not repeat those in the annual statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. The changes in accounting policies in the Company’s unaudited condensed consolidated interim financial statements from the March 31, 2019 audited financial statements are described below. Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014‑09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014‑09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014‑09, as amended, is effective for the Company in the interim period ended September 30, 2019. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU‑2014‑1 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet and the consolidated results of operations. In November 2015, the FASB issued ASU No. 2015‑17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015‑17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU‑2015‑17 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016‑01 Financial Instruments - Overall (Subtopic 825‑10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825‑10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU 2016‑01 for the year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet and the consolidated results of operations. In February 2016, the FASB issued ASU 2016‑02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company has adopted ASU 2016‑02 and it did not have a material effect on the consolidated balance sheet and consolidated statement of operations. In August 2016, the FASB issued ASU 2016‑15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016‑15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU 2016‑15 for the fiscal year ended March 31, 2019 and it did not have material effect on the consolidated balance sheet or on the consolidated statement of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted ASU 2017-09 during the year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet and the consolidated results of operations. Recently Issued In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after September 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated balance sheet or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2017-04 will have on the consolidated balance sheet and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2016-13 will have on the consolidated balance sheet and consolidated statement of operations. Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the condensed consolidated interim balance sheets and amounted to $165,207 at September 30, 2019 (March 31, 2019 - $143,500). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $26,912 of expenses related to warranty expenses and recorded this expense in cost of goods sold for the six-month period ended September 30, 2019 (September 30, 2018 – $10,108).

TECHNOLOGY AND OTHER ASSETS

TECHNOLOGY AND OTHER ASSETS	6 Months Ended
	Sep. 30, 2019
TECHNOLOGY AND OTHER ASSETS
TECHNOLOGY AND OTHER ASSETS	4. TECHNOLOGY AND OTHER ASSETS The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the six months ended September 30, 2019, and the year ended March 31, 2019: Amortization Value Amortization Value at Amortization Value at period (years) Acquired March 31, 2019 March 31, 2019 September 30, 2019 September 30, 2019 Intangible assets acquired $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,090 911,440 67,044 844,396 Trademark Indefinite 2,505,907 — 2,505,907 — 2,505,907 Customer relationships 10 1,431,680 143,168 1,010,375 71,584 938,791 Non compete agreement 2 61,366 1,739 — — — Assembled workforce 1 275,720 — — — — 5,580,704 278,997 4,427,722 138,628 4,289,094 Amortization expense for the technology and other assets was $138,628 and $140,368 for the six months ended September 30, 2019 and 2018, respectively. Amortization expensed for the technology and other assets was $69,314 and $69,315 for the three months ended September 30, 2019 and 2018, respectively.

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	6 Months Ended
	Sep. 30, 2019
PREPAID EXPENSES AND OTHER RECEIVABLES
PREPAID EXPENSES AND OTHER RECEIVABLES	5. PREPAID EXPENSES AND OTHER RECEIVABLES September 30, March 31, 2019 2019 $ $ Prepaid expenses and other receivables 147,858 92,170 Prepaid inventory 1,897,873 1,144,392 Prepaid insurance 117,343 66,320 Sales taxes receivable (i) 29,103 52,150 2,192,177 1,355,032 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES

INVENTORIES	6 Months Ended
	Sep. 30, 2019
INVENTORIES
INVENTORIES	6. INVENTORIES September 30, March 31, 2019 2019 Finished Goods 1,037,058 405,682 During the three and six month period ended September 30, 2019, the Company expensed $76,843 and $376,639 in inventory as cost of goods sold (September 30, 2018 - $342,345 and $579,354). The Company no longer maintains a raw materials inventory as it has outsourced its manufacturing to a third party.

EQUIPMENT

EQUIPMENT	6 Months Ended
	Sep. 30, 2019
EQUIPMENT
EQUIPMENT	7. EQUIPMENT Equipment consisted of the following as at September 30, 2019 and March 31, 2019: September 30, 2019 March 31, 2019 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 296,917 253,648 43,269 286,855 243,346 43,509 Furniture and fixtures 36,795 30,333 6,462 36,795 29,648 7,147 Demonstration equipment 352,694 184,311 168,383 271,615 147,257 124,358 Manufacturing equipment 88,742 86,471 2,271 88,742 86,230 2,512 Tools and parts 11,422 7,224 4,198 11,422 6,779 4,643 Assets under capital lease 23,019 14,962 8,057 23,019 12,660 10,359 809,589 576,949 232,640 718,448 525,920 192,528 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three-and six month period ended September 30, 2019 was $27,059 and $51,029 (September 30, 2018-$16,626 and $34,221, respectively).

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Sep. 30, 2019
NOTES PAYABLE
NOTES PAYABLE	8. NOTES PAYABLE (a) Convertible Loans Payable During the six months ended September 30, 2019, the Company received loans from new and existing investors totaling $9,000,000 pursuant to an up to $9,000,000 convertible note offering. This included the conversion and satisfaction of an existing $500,000 term loan at June 30, 2019. The convertible notes bore interest at a fixed rate of 1% per month until September 30, 2019 and $6,070,000 of these convertible notes were converted into common shares of the Company on September 30, 2019 at a conversion price of $6.80 per share and $2,930,000 of these convertible notes were converted into common shares of the Company on September 30, 2019 at a conversion price of $8.265. The interest accrued on these convertible loans for the three and six months ended September 30, 2019 was $139,477 and $143,927 respectively and the interest was converted into shares at the respective conversion prices. In the event the Company raises capital through the sale of Common Stock for cash during the period ending on the three year anniversary of the earliest issuance date of the convertible notes, and the price per share thereof (the “ Offering Price ”) is less than the original Conversion Price, then in such event the Company shall issue to all convertible loan holder at, at no further cost, additional shares of common stock equal to the number of conversion shares the holders would have received upon conversion if the Conversion Price equaled the Offering Price, less the number of shares of conversion shares actually issued on or as of the Maturity Date. Since the Company has early adopted ASU 2017-11, the anti-dilution protection clause does not contribute to the conversion feature to be a derivative liability. March 31, 2019 — Convertible loans issued $ 9,000,000 Interest 143,927 Convertible loans and interest converted in 1,268,191 shares (9,143,927) September 30, 2019 $ — (b) Convertible Loans Payable During the six months ended September 30, 2019, the Company received $70,000 from an existing investor pursuant to a $3,000,000 (or up to $7,000,000 at the discretion of the Company) convertible note offering. The convertible notes bear interest at a fixed rate at 1% per month and will be payable, along with the principal amount on the earlier of (the “Maturity Date”); (a) March 20, 2020 and (b) the consummation of the offering provided that the Company raises in one or more tranches aggregate gross proceeds of no less than $3,000,000. The convertible loans will be convertible into equity of the Company upon the following events on the following terms: (i) On the Maturity Date, the outstanding principal and accrued and unpaid interest under the convertible note will be converted into shares of common stock at a conversion price of $8.55 per shares in the event of an investment on or prior to September 30, 2019, and $9.50 per share in the event of an investment after September 30, 2019. (the Conversion Price”). (j) Upon change of control transaction prior to the Maturity Date, the outstanding principal and accrued and unpaid interest under the convertible notes would, at the election of the holders of a majority of the outstanding principal of the loans under the offering, be either (i) payable upon demand as of the closing of such change of control transaction or (ii) convertible into shares of the Company’s common stock immediately prior to such change of control transaction at a price per share equal to the lesser of (x) the Conversion Price or (y) the per share consideration to be received by the holders of the common stock in such change of control transaction. The interest accrued on these convertible loans for the six months ended September 30, 2019 was $117.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	6 Months Ended
	Sep. 30, 2019
RELATED PARTY TRANSACTIONS AND BALANCES
RELATED PARTY TRANSACTIONS AND BALANCES	9. RELATED PARTY TRANSACTIONS AND BALANCES (a) Due from related parties At September 30, 2019 there was an outstanding loan to the Chief Technology Officer ("CTO") of the Company of $18,932 (March 31, 2019 – $18,585). The loan had an interest rate of 1% until June 30, 2018 and 2% after this date based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the six month period ended September 30, 2019, the Company accrued interest receivable in the amount of $236 (March 31, 2019 – $353); the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. (b) Accounts payable and accrued liabilities As at September 30, 2019, $1,957 (March 31, 2019 – $229,473) was owing to the CEO of the Company; $12,813 (March 31, 2019 – $14,851) was owing to the Chief Technology Officer; $1,845 (March 31, 2019 – $33,387) was owing to the Chief Financial Officer ("CFO"), $Nil (March 31, 2019 - $28,025) was owing to the current and former Chief Commercial Officer ("CCO"), all related to bonuses and business expenses. All bonuses accrued at March 31, 2019 have been paid.

SHARE CAPITAL

SHARE CAPITAL	6 Months Ended
	Sep. 30, 2019
SHARE CAPITAL
SHARE CAPITAL	10. SHARE CAPITAL September 30, 2019 March 31, 2019 Number of Number of shares $ shares $ Exchangeable Shares Balance beginning of year 196,799 197 295,146 295 Converted into common shares (a) (40,560) (41) (98,347) (98) Balance at end of year 156,239 156 196,799 197 Common Shares Balance at beginning of the year 3,661,838 3,661 1,368,856 1,369 Shares issued to exchangeable shareholders (a) 40,560 41 98,347 98 Shares issued on conversion of loans 1,268,191 1,268 2,194,133 2,194 Share consolidation rounding adjustment 6 — 502 — Balance at end of the year 4,970,595 4,970 3,661,838 3,661 TOTAL SHARES 5,126,834 5,126 3,858,637 3,858 (a) During the six months ended September 30, 2019, 40,560 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2019 – 98,347 shares) (b) On September 30, 2019 $9,143,927 of promissory notes and interest were converted into 1,268,191 common shares. These shareholders have price protection until June 10, 2022. (c) On October 29, 2018, the Company completed a one-for-one hundred and fifty (1:150) reverse stock consolidation that has been reflected in all shares and per share amounts, warrants and options. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation and is not convertible into shares of common stock of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement and the Special Voting Preferred Share will be automatically cancelled.

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
	Sep. 30, 2019
STOCK OPTIONS
STOCK OPTIONS	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On April 26, 2016, the Company issued 1,667 options to an employee with an exercise price of $150.00 per share that will vest over three years at the anniversary date. The grant fair value was $213,750. During the three and six months ended September 30, 2019 $Nil and $3,431 (September 30, 2018 - $17,813 and $35,625) was recognized as stock compensation expense due to the employee leaving the Company. On February 6, 2017, the Company issued 2,667 options to an employee with an exercise price of $105.00 per share that will vest over three years at the anniversary date. The grant fair value was $245,200. During the three and six months ended September 30, 2019 $20,433 and $40,867 (September 30, 2018 – $20,433 and $40,867) of stock compensation expense was recognized. On September 1, 2017, the Company granted 81,436 options at $24.15 per share equally to an executive officer and a consultant, who is now the Chairman of the Company. 27,148 options have vested and 50% of the remaining options vest on performance being met and 50% vest annually over 5 years for the CEO, for our Chairman the options vest over 5 years. The grant date fair value was $1,832,304 and $133,605 and $190,865 is the current expense for the three and six months ended September 30, 2019 (September 30, 2018 - $190,865 and $229,037. On January 24, 2018, the Company granted 24,267 options at $23.25 per share to employees that vest equally on January 24, 2019, 2020 and 2021. 7,334 options were cancelled for the year ended March 31, 2019 and 778 for the three and six month period ended September 30, 2019. The grant fair value was $491,036 and $26,306 and $54,860 is the current stock compensation expense for the three and six months ended September 30, 2019 (September 30, 2018 - $37,266 and $76,968). On April 30, 2018, the Company granted to an executive officer, 40,000 options with an exercise price of $9.74 that vest immediately with a 10‑year expiry. These options were valued using the Black Scholes model and the following inputs were used: expected life 10 years, expected volatility 114% and a risk-free rate of 1.59%. As these options vested immediately as of the grant date and $363,714 of stock compensation expense was recorded for the year ended March 31, 2019. On June 11, 2018, the Company granted to an executive officer, 5,000 options with an exercise price of $6.93 per share that vest over three years from the anniversary of the grant and expire in 7 years. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk -free rate of 1.59%. The grant fair value was $30,341 and $Nil and $1,686 of stock compensation was recognized for three and six months ended September 30, 2019 (September 30, 2018 $2,528 and $3,090).This executive left the Company and all 5,000 options were cancelled, as they had not vested. On May 31, 2019 169,882 options were issued to employees and directors of the Company with an exercise price of $3.16 per share that vest over 18 months,with one third immediately vesting and one third vesting in each of the following two 6-month periods and expire in 7 years. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $453,585 and $84,601 and $260,995 of stock compensation was recognized for three and six months ended September 30, 2019. On July 26, 2019, 484,612 options were granted to employees and consultants at an exercise price of $3.595. The options were using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $1,525,525 and $372,923 of stock compensation was recognized for three and six months ended September 30, 2019. On September 3, 2019, 5,000 options were granted to an employee at an exercise price of $3.20 which vest over three years starting September 3, 2020. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $14,010 and $350 of stock compensation was recognized for the three and six months ended September 30, 2019 During the three and six months ended September 30, 2019, the Company recorded $638,219 and $925,976 in share-based compensation related to the vesting of stock options (September 30, 2018 – $439,328 and $1,034,740). The following is a summary of stock options outstanding and exercisable as of September 30, 2019: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 105.000 2,667 06-Feb-24 1,778 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 485 30-Sep-24 485 157.500 1,876 30-Sep-24 1,876 24.150 81,436 01-Sep-27 40,722 23.250 15,822 24-Jan-25 5,533 9.735 40,000 19-Apr-28 40,000 3.16 169,549 31-May-26 56,629 3.595 484,612 26-Jul-26 58,639 3.20 5,000 03-Sep-26 — 834,434 238,649 The weighted-average remaining contractual term of the outstanding options is 6.78 years (March 31, 2019 – 7.20 years) and for the options that are exercisable the weighted average is 6.62 years (March 31, 2019 – 5.74 years).

WARRANTS

WARRANTS	6 Months Ended
	Sep. 30, 2019
WARRANTS
WARRANTS	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Weighted Average Number of Exercise Price Warrants ($) Outstanding and exercisable, March 31, 2018 and September 30, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected warrant transaction 6,305 34.50 Issued in connection with anti-dilution provision connected warrant transaction 52,590 38.91 Expired (204,304) (51.85) Outstanding and exercisable, March 31, 2019 288,517 40.27 Expired (163,483) (38.91) Outstanding and exercisable, September 30, 2019 125,034 20.07 During the six months ended September 30, 2019, 163,483 warrants expired in accordance with their terms (September 30, 2018 – Nil) Common share purchase warrants The following is a summary of common share purchase warrants outstanding as of September 30, 2019. Exercise Number of Price ($) Warrants Expiry Date 90.00 15,658 March 31, 2023 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 125,034 The weighted-average remaining contractual term of the outstanding warrants was 2.82 years (March 31, 2019 – 1.51 years).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 30, 2019
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments (a) On February 25, 2015, 1,753 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan, the Company's then-CTO and COO had transferred 2,098 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former CTO and COO 2,134 common shares. As at September 30, 2019 these shares have not yet been issued. (b) On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form China Bionik Medical Rehabilitation Technology Ltd. (“China JV”), in which the Company will have a 25% interest and the JV Partner 75%. The China JV was formally established on receiving a business license on May 22, 2018. Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of the date of establishment, $435,000 12 months later and $725,000, 60 months after the date of establishment. The Company is required to license certain intellectual property to the China JV. The Company is applying the equity method of accounting to the joint venture. As of September 30, 2019, the Company has provided certain technical information to the Chinese JV in order to obtain Chinese regulatory approvals. (c) In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, with a former director as a co- licenser, pursuant to which the Company pays the director and the co-licenser an aggregate royalty of 1% of sales based on patent #8,613,691. No sales have been made, as the technology under this patent has not been commercialized. (d) The Company has committed to upgrading two robots previously sold to a customer to the newest version when released. As part of this transaction, the customer will enter into an extended warranty agreement that will be approximately equal to the manufacturing value of robots. These 2 robots were shipped in November, 2019 and the warranty revenue will be recognized over the term of the warranty.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Sep. 30, 2019
SIGNIFICANT ACCOUNTING POLICIES
Unaudited Condensed Consolidated Interim Financial Statements	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10‑K for the year ended March 31, 2019. The interim disclosures generally do not repeat those in the annual statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. The changes in accounting policies in the Company’s unaudited condensed consolidated interim financial statements from the March 31, 2019 audited financial statements are described below.
Newly Adopted and Recently Issued Accounting Pronouncements	Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014‑09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014‑09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014‑09, as amended, is effective for the Company in the interim period ended September 30, 2019. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU‑2014‑1 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet and the consolidated results of operations. In November 2015, the FASB issued ASU No. 2015‑17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015‑17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU‑2015‑17 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016‑01 Financial Instruments - Overall (Subtopic 825‑10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825‑10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU 2016‑01 for the year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet and the consolidated results of operations. In February 2016, the FASB issued ASU 2016‑02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company has adopted ASU 2016‑02 and it did not have a material effect on the consolidated balance sheet and consolidated statement of operations. In August 2016, the FASB issued ASU 2016‑15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016‑15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU 2016‑15 for the fiscal year ended March 31, 2019 and it did not have material effect on the consolidated balance sheet or on the consolidated statement of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted ASU 2017-09 during the year ended March 31, 2019 and it did not have a material effect on the consolidated balance sheet and the consolidated results of operations.
Recently Issued	Recently Issued In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after September 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated balance sheet or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2017-04 will have on the consolidated balance sheet and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2016-13 will have on the consolidated balance sheet and consolidated statement of operations.
Warranty Reserve and Deferred Warranty Revenue	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the condensed consolidated interim balance sheets and amounted to $165,207 at September 30, 2019 (March 31, 2019 - $143,500). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $26,912 of expenses related to warranty expenses and recorded this expense in cost of goods sold for the six-month period ended September 30, 2019 (September 30, 2018 – $10,108).

TECHNOLOGY AND OTHER ASSETS (Ta

TECHNOLOGY AND OTHER ASSETS (Tables)	6 Months Ended
	Sep. 30, 2019
TECHNOLOGY AND OTHER ASSETS
Schedule of intangible assets acquired in the IMT acquisition	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the six months ended September 30, 2019, and the year ended March 31, 2019: Amortization Value Amortization Value at Amortization Value at period (years) Acquired March 31, 2019 March 31, 2019 September 30, 2019 September 30, 2019 Intangible assets acquired $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,090 911,440 67,044 844,396 Trademark Indefinite 2,505,907 — 2,505,907 — 2,505,907 Customer relationships 10 1,431,680 143,168 1,010,375 71,584 938,791 Non compete agreement 2 61,366 1,739 — — — Assembled workforce 1 275,720 — — — — 5,580,704 278,997 4,427,722 138,628 4,289,094

PREPAID EXPENSES AND OTHER RE_2

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	6 Months Ended
	Sep. 30, 2019
PREPAID EXPENSES AND OTHER RECEIVABLES
Schedule of prepaid expenses and other receivables	September 30, March 31, 2019 2019 $ $ Prepaid expenses and other receivables 147,858 92,170 Prepaid inventory 1,897,873 1,144,392 Prepaid insurance 117,343 66,320 Sales taxes receivable (i) 29,103 52,150 2,192,177 1,355,032 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Sep. 30, 2019
INVENTORIES
Schedule of inventory	September 30, March 31, 2019 2019 Finished Goods 1,037,058 405,682

EQUIPMENT (Tables)

EQUIPMENT (Tables)	6 Months Ended
	Sep. 30, 2019
EQUIPMENT
Schedule of components of equipment	Equipment consisted of the following as at September 30, 2019 and March 31, 2019: September 30, 2019 March 31, 2019 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 296,917 253,648 43,269 286,855 243,346 43,509 Furniture and fixtures 36,795 30,333 6,462 36,795 29,648 7,147 Demonstration equipment 352,694 184,311 168,383 271,615 147,257 124,358 Manufacturing equipment 88,742 86,471 2,271 88,742 86,230 2,512 Tools and parts 11,422 7,224 4,198 11,422 6,779 4,643 Assets under capital lease 23,019 14,962 8,057 23,019 12,660 10,359 809,589 576,949 232,640 718,448 525,920 192,528

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Sep. 30, 2019
NOTES PAYABLE
Summary of convertible loans payable	March 31, 2019 — Convertible loans issued $ 9,000,000 Interest 143,927 Convertible loans and interest converted in 1,268,191 shares (9,143,927) September 30, 2019 $ —

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	6 Months Ended
	Sep. 30, 2019
SHARE CAPITAL
Schedule of share capital	September 30, 2019 March 31, 2019 Number of Number of shares $ shares $ Exchangeable Shares Balance beginning of year 196,799 197 295,146 295 Converted into common shares (a) (40,560) (41) (98,347) (98) Balance at end of year 156,239 156 196,799 197 Common Shares Balance at beginning of the year 3,661,838 3,661 1,368,856 1,369 Shares issued to exchangeable shareholders (a) 40,560 41 98,347 98 Shares issued on conversion of loans 1,268,191 1,268 2,194,133 2,194 Share consolidation rounding adjustment 6 — 502 — Balance at end of the year 4,970,595 4,970 3,661,838 3,661 TOTAL SHARES 5,126,834 5,126 3,858,637 3,858 (a) During the six months ended September 30, 2019, 40,560 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2019 – 98,347 shares) (b) On September 30, 2019 $9,143,927 of promissory notes and interest were converted into 1,268,191 common shares. These shareholders have price protection until June 10, 2022. (c) On October 29, 2018, the Company completed a one-for-one hundred and fifty (1:150) reverse stock consolidation that has been reflected in all shares and per share amounts, warrants and options.

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
	Sep. 30, 2019
STOCK OPTIONS
Schedule of stock options outstanding and exercisable	The following is a summary of stock options outstanding and exercisable as of September 30, 2019: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 105.000 2,667 06-Feb-24 1,778 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 485 30-Sep-24 485 157.500 1,876 30-Sep-24 1,876 24.150 81,436 01-Sep-27 40,722 23.250 15,822 24-Jan-25 5,533 9.735 40,000 19-Apr-28 40,000 3.16 169,549 31-May-26 56,629 3.595 484,612 26-Jul-26 58,639 3.20 5,000 03-Sep-26 — 834,434 238,649

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Sep. 30, 2019
WARRANTS
Schedule of continuity schedule	The following is a continuity schedule of the Company’s common share purchase warrants: Weighted Average Number of Exercise Price Warrants ($) Outstanding and exercisable, March 31, 2018 and September 30, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected warrant transaction 6,305 34.50 Issued in connection with anti-dilution provision connected warrant transaction 52,590 38.91 Expired (204,304) (51.85) Outstanding and exercisable, March 31, 2019 288,517 40.27 Expired (163,483) (38.91) Outstanding and exercisable, September 30, 2019 125,034 20.07
Schedule of common share purchase warrants outstanding	The following is a summary of common share purchase warrants outstanding as of September 30, 2019. Exercise Number of Price ($) Warrants Expiry Date 90.00 15,658 March 31, 2023 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 125,034

NATURE OF OPERATIONS AND GOIN_2

NATURE OF OPERATIONS AND GOING CONCERN (Details)	Oct. 29, 2018	Apr. 21, 2016shares	Feb. 26, 2015shares	Feb. 25, 2015shares	Feb. 13, 2015	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Mar. 31, 2019USD ($)shares	Jun. 12, 2018shares	Nov. 06, 2017shares	Mar. 31, 2017shares	Dec. 31, 2014shares
Common Stock, Shares Authorized						500,000,000		500,000,000		500,000,000	500,000,000	250,000,000	150,000,000	200,000,000
Reverse stock split ratio	0.0067				0.831105
Stock Issued During Period, Shares, New Issues				1,753
Working Capital Surplus (Deficit) | $						$ 5,144,499		$ 5,144,499		$ 479,408
Retained Earnings (Accumulated Deficit) | $						(51,860,701)		(51,860,701)		$ (46,357,373)
Comprehensive Income (Loss), Net of Tax | $						$ (3,382,684)	$ (3,983,105)	$ (5,503,328)	$ (4,743,803)
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		157,667
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues			333,334
Exchange ratio of exchangeable shares to common shares outstanding			3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage			100.00%

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	Oct. 29, 2018	Feb. 13, 2015	Sep. 30, 2019$ / shares	Mar. 31, 2019$ / shares
BASIS OF PRESENTATION
Common Stock, Par or Stated Value Per Share			$ 0.001	$ 0.001
Stockholders' Equity Note, Stock Split, Conversion Ratio	0.0067	0.831105

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	6 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Mar. 31, 2019
SIGNIFICANT ACCOUNTING POLICIES
Standard and Extended Product Warranty Accrual	$ 165,207		$ 143,500
Product Warranty Expense	$ 26,912	$ 10,108

TECHNOLOGY AND OTHER ASSETS - I

TECHNOLOGY AND OTHER ASSETS - Intangible assets acquired (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Mar. 31, 2019
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			$ 5,580,704
Amortization of Intangible Assets	$ 69,314	$ 69,315	138,628	$ 140,368	$ 278,997
Intangible Assets, Net (Excluding Goodwill)	4,289,094		$ 4,289,094		4,427,722
Patents and Exclusive License Agreement [Member]
Finite-Lived Intangible Asset, Useful Life			9 years 8 months 27 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			$ 1,306,031
Amortization of Intangible Assets			67,044		134,090
Intangible Assets, Net (Excluding Goodwill)	844,396		844,396		911,440
Trademarks [Member]
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			2,505,907
Amortization of Intangible Assets			0		0
Intangible Assets, Net (Excluding Goodwill)	2,505,907		$ 2,505,907		2,505,907
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life			10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			$ 1,431,680
Amortization of Intangible Assets			71,584		143,168
Intangible Assets, Net (Excluding Goodwill)	938,791		$ 938,791		1,010,375
Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life			2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			$ 61,366
Amortization of Intangible Assets			0		1,739
Intangible Assets, Net (Excluding Goodwill)	0		$ 0		0
Assembled Workforce [Member]
Finite-Lived Intangible Asset, Useful Life			1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			$ 275,720
Amortization of Intangible Assets			0		0
Intangible Assets, Net (Excluding Goodwill)	$ 0		$ 0		$ 0

TECHNOLOGY AND OTHER ASSETS - A

TECHNOLOGY AND OTHER ASSETS - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Mar. 31, 2019
TECHNOLOGY AND OTHER ASSETS
Amortization of Intangible Assets	$ 69,314	$ 69,315	$ 138,628	$ 140,368	$ 278,997

PREPAID EXPENSES AND OTHER RE_3

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)	Sep. 30, 2019	Mar. 31, 2019
PREPAID EXPENSES AND OTHER RECEIVABLES
Prepaid expenses and other receivables	$ 147,858	$ 92,170
Prepaid inventory	1,897,873	1,144,392
Prepaid insurance	117,343	66,320
Sales taxes receivable	29,103	52,150
Sales taxes receivable (i)	$ 2,192,177	$ 1,355,032

Inventories- Schedule of Invent

Inventories- Schedule of Inventories (Details) - USD ($)	Sep. 30, 2019	Mar. 31, 2019
INVENTORIES
Finished Goods	$ 1,037,058	$ 405,682

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Cost of Goods and Services Sold	$ 83,207	$ 384,073	$ 419,292	$ 637,236
Inventory Cost [Member]
Cost of Goods and Services Sold	$ 76,843	$ 342,345	$ 376,639	$ 579,354

EQUIPMENT - Schedule of net equ

EQUIPMENT - Schedule of net equipment (Details) - USD ($)	Sep. 30, 2019	Mar. 31, 2019
Equipment [Line Items]
Equipment, Cost	$ 809,589	$ 718,448
Accumulated Depreciation	576,949	525,920
Equipment, Net	232,640	192,528
Computer and electronics [Member]
Equipment [Line Items]
Equipment, Cost	296,917	286,855
Accumulated Depreciation	253,648	243,346
Equipment, Net	43,269	43,509
Furniture and fixtures [Member]
Equipment [Line Items]
Equipment, Cost	36,795	36,795
Accumulated Depreciation	30,333	29,648
Equipment, Net	6,462	7,147
Demonstration equipment [Member]
Equipment [Line Items]
Equipment, Cost	352,694	271,615
Accumulated Depreciation	184,311	147,257
Equipment, Net	168,383	124,358
Manufacturing Equipment [Member]
Equipment [Line Items]
Equipment, Cost	88,742	88,742
Accumulated Depreciation	86,471	86,230
Equipment, Net	2,271	2,512
Tools and parts [Member]
Equipment [Line Items]
Equipment, Cost	11,422	11,422
Accumulated Depreciation	7,224	6,779
Equipment, Net	4,198	4,643
Assets under capital lease [Member]
Equipment [Line Items]
Equipment, Cost	23,019	23,019
Accumulated Depreciation	14,962	12,660
Equipment, Net	$ 8,057	$ 10,359

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
EQUIPMENT
Depreciation	$ 27,059	$ 16,626	$ 51,029	$ 34,221

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2019	Oct. 01, 2019
Debt Instrument [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities				$ 9,143,927
Term Loan [Member]
Debt Instrument [Line Items]
Convertible notes converted into common shares			$ 500,000
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Convertible notes converted into common shares	$ 9,143,927			$ 9,143,927
Debt Instrument, Interest Rate, Stated Percentage	1.00%	1.00%		1.00%
Interest		$ 139,477		$ 143,927
Convertible note offering	$ 9,000,000	9,000,000		$ 9,000,000
Shares issued in conversion of loans	1,268,191			1,268,191
Convertible Loans Payable [Member] | Investors [Member]
Debt Instrument [Line Items]
Convertible loans received	$ 9,000,000	9,000,000		$ 9,000,000
Convertible note offering	$ 9,000,000	$ 9,000,000		9,000,000
Convertible Loans Payable with Conversion Price One [Member]
Debt Instrument [Line Items]
Convertible notes converted into common shares				$ 6,070,000
Debt Instrument, Convertible, Conversion Price	$ 6.80	$ 6.80		$ 6.80
Convertible Loans Payable with Conversion Price Two [Member]
Debt Instrument [Line Items]
Convertible notes converted into common shares				$ 2,930,000
Debt Instrument, Interest Rate, Stated Percentage	8.265%	8.265%		8.265%
Convertible Loans Payable Two [Member]
Debt Instrument [Line Items]
Interest				$ 117
Convertible Loans Payable Two [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Debt Instrument [Line Items]
Convertible loans received	$ 70,000	$ 70,000		$ 70,000
Debt Instrument, Interest Rate, Stated Percentage	1.00%	1.00%		1.00%
Convertible note offering	$ 3,000,000	$ 3,000,000		$ 3,000,000
Convertible loans issued at the discretion of the Company	$ 7,000,000	$ 7,000,000		7,000,000
Proceeds from Sale of Available-for-sale Securities				$ 3,000,000
Convertible Loans Payable with Conversion Price Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 8.55	$ 8.55		$ 8.55
Convertible Loans Payable with Conversion Price Four [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 9.50

Notes payable - Conversion of N

Notes payable - Conversion of Notes Payable (Details) - Convertible Loans Payable [Member]	Sep. 30, 2019USD ($)shares	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)shares
Convertible loans issued	$ 9,000,000	$ 9,000,000	$ 9,000,000
Interest		$ 139,477	143,927
Convertible loans and interest converted in 1,268,191 shares	$ (9,143,927)		$ (9,143,927)
Shares issued in conversion of loans | shares	1,268,191		1,268,191

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details) - USD ($)	Mar. 31, 2019	Jun. 30, 2018	Sep. 30, 2019
RELATED PARTY TRANSACTIONS AND BALANCES
Accrued interest receivable	$ 353		$ 236
Chief Executive Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Accounts Payable, Related Parties	229,473		1,957
Chief Technology Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Due from Related Parties	18,585		18,932
Accounts Payable, Related Parties	14,851		$ 12,813
Related Party Transaction, Rate		1.00%	2.00%
Chief Financial Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Accounts Payable, Related Parties	33,387		$ 1,845
Chief Commercial Officer [Member]
RELATED PARTY TRANSACTIONS AND BALANCES
Accounts Payable, Related Parties	$ 28,025		$ 0

SHARE CAPITAL - Summary of exch

SHARE CAPITAL - Summary of exchangeable and common shares (Details) - USD ($)	6 Months Ended			12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2019
Opening Balance	$ 27,407,933	$ 26,897,455	$ 20,463,014	$ 20,463,014
Shares issued on conversion of loans	9,143,927
Closing Balance	$ 31,974,508	$ 27,407,933	$ 26,897,455	$ 27,407,933
Exchangeable Shares [Member]
Opening Balance (in shares)	196,799		295,146	295,146
Opening Balance	$ 197		$ 295	$ 295
Converted into common shares (in shares)	(40,560)			(98,347)
Converted into common shares	$ (41)			$ (98)
Closing Balance (in shares)	156,239	196,799		196,799
Closing Balance	$ 156	$ 197		$ 197
Common Shares [Member]
Opening Balance (in shares)	3,661,838		1,368,856	1,368,856
Opening Balance	$ 3,661		$ 1,369	$ 1,369
Shares issued on conversion of loans (in shares)	40,560			98,347
Shares issued on conversion of loans	$ 41			$ 98
Shares issued on conversion of loans (in shares)	1,268,191			2,194,133
Shares issued on conversion of loans	$ 1,268			$ 2,194
Share consolidation rounding adjustment (in shares)	6			502
Share consolidation rounding adjustment	$ 0			$ 0
Closing Balance (in shares)	4,970,595	3,661,838		3,661,838
Closing Balance	$ 4,970	$ 3,661		$ 3,661
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)	3,858,637
Opening Balance	$ 3,858
Closing Balance (in shares)	5,126,834	3,858,637		3,858,637
Closing Balance	$ 5,126	$ 3,858		$ 3,858

SHARE CAPITAL - Additional Info

SHARE CAPITAL - Additional Information (Details)	Sep. 30, 2019USD ($)shares	Mar. 31, 2019shares	Oct. 29, 2018	Feb. 13, 2015	Sep. 30, 2019USD ($)shares	Mar. 31, 2019shares	Sep. 30, 2018USD ($)shares
Reverse stock split ratio			0.0067	0.831105
Loss on Mark to Market Reevaluation | $					$ 0		$ (2,048,697)
Exchangeable Shares exchanged for common shares		98,347			40,560
Convertible Loans Payable [Member]
Debt Conversion, Original Debt, Amount | $	$ 9,143,927				$ 9,143,927
Number of Shares Converted	1,268,191				1,268,191
Common Shares [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities					1,268,191
Common Shares [Member] | Convertible Debt One [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities							683,395
Common Shares [Member] | Convertible Debt Two [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						1,247,099

STOCK OPTIONS - Summary of stoc

STOCK OPTIONS - Summary of stock options outstanding and exercisable (Details)	6 Months Ended
	Sep. 30, 2019$ / sharesshares
STOCK OPTIONS
Number of Options	834,434
Exercisable Options	238,649
Stock Option One [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 34.500
Number of Options	630
Expiry Date	Jun. 20, 2021
Exercisable Options	630
Stock Option Two [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 34.500
Number of Options	13,212
Expiry Date	Jul. 1, 2021
Exercisable Options	13,212
Stock Option Three [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 34.500
Number of Options	944
Expiry Date	Feb. 17, 2022
Exercisable Options	944
Stock Option Four [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 183
Number of Options	2,667
Expiry Date	Nov. 24, 2022
Exercisable Options	2,667
Stock Option Five [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 150
Number of Options	11,400
Expiry Date	Dec. 14, 2022
Exercisable Options	11,400
Stock Option Six [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	359
Expiry Date	Mar. 28, 2023
Exercisable Options	359
Stock Option Seven [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	1,387
Expiry Date	Mar. 28, 2023
Exercisable Options	1,387
Stock Option Eight [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 105
Number of Options	2,667
Expiry Date	Feb. 6, 2024
Exercisable Options	1,778
Stock Option Nine [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 102
Number of Options	1,667
Expiry Date	Feb. 13, 2024
Exercisable Options	1,667
Stock Option Ten [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	106
Expiry Date	Mar. 3, 2024
Exercisable Options	106
Stock Option Eleven [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	408
Expiry Date	Mar. 3, 2024
Exercisable Options	408
Stock Option Twelve [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	43
Expiry Date	Mar. 14, 2024
Exercisable Options	43
Stock Option Thirteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	164
Expiry Date	Mar. 14, 2024
Exercisable Options	164
Stock Option Fourteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 142.500
Number of Options	485
Expiry Date	Sep. 30, 2024
Exercisable Options	485
Stock Option Fifteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 157.500
Number of Options	1,876
Expiry Date	Sep. 30, 2024
Exercisable Options	1,876
Stock Option Sixteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 24.150
Number of Options	81,436
Expiry Date	Sep. 1, 2027
Exercisable Options	40,722
Stock Option Seventeen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 23.250
Number of Options	15,822
Expiry Date	Jan. 24, 2025
Exercisable Options	5,533
Stock Option Eighteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 9.735
Number of Options	40,000
Expiry Date	Apr. 19, 2028
Exercisable Options	40,000
Stock Option Nineteen [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 3.16
Number of Options	169,549
Expiry Date	May 31, 2026
Exercisable Options	56,629
Stock Option Twenty [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 3.595
Number of Options	484,612
Expiry Date	Jul. 26, 2026
Exercisable Options	58,639
Stock Option Twenty One [Member]
STOCK OPTIONS
Exercise Price | $ / shares	$ 3.20
Number of Options	5,000
Expiry Date	Sep. 3, 2026
Exercisable Options	0

STOCK OPTIONS - Additional Info

STOCK OPTIONS - Additional Information (Details) - USD ($)

Sep. 03, 2019

Jul. 26, 2019

May 31, 2019

Jun. 11, 2018

Apr. 30, 2018

Jan. 24, 2018

Sep. 01, 2017

Feb. 06, 2017

Apr. 26, 2016

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Mar. 31, 2019

STOCK OPTIONS

Maximum percentage of common stock and exchangeable shares issued and outstanding that may be reserved for issuance upon exercise of all options or other securities granted

15.00%

15.00%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

24,267

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

834,434

834,434

Allocated Share-based Compensation Expense

$ 26,306

$ 37,266

$ 54,860

$ 76,968

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

6 years 9 months 11 days

7 years 2 months 12 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

6 years 7 months 13 days

5 years 8 months 27 days

Grant fair value

$ 491,036

Employee Stock Option [Member]

STOCK OPTIONS

Allocated Share-based Compensation Expense

638,219

439,328

$ 925,976

1,034,740

New Executive Officer [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

5,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 6.93

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

5,000

Allocated Share-based Compensation Expense

0

2,528

1,686

3,090

Grant fair value

$ 30,341

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Executive Officer [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

40,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 9.74

Allocated Share-based Compensation Expense

$ 363,714

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Employees of Bionik Inc [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,667

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 150

Allocated Share-based Compensation Expense

$ 0

17,813

3,431

35,625

Grant fair value

$ 213,750

Employees [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

778

7,334

Director and Employees [Member]

STOCK OPTIONS

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 3.16

Allocated Share-based Compensation Expense

$ 84,601

260,995

Grant fair value

$ 453,585

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

169,882

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Director and Employees [Member] | Minimum [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

6 months

Director and Employees [Member] | Maximum [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

18 months

Employee Two [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,667

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 105

Allocated Share-based Compensation Expense

20,433

20,433

40,867

40,867

Grant fair value

$ 245,200

Executive Employee And Consultant [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

81,436

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 24.15

Allocated Share-based Compensation Expense

133,605

$ 190,865

190,865

229,037

Grant fair value

$ 1,832,304

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

50.00%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

27,148

Executive Employee And Consultant [Member] | Share-based Payment Arrangement, Tranche Two [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

50.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Employees and consultants [Member] | Employee Stock Option [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

484,612

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 3.595

Allocated Share-based Compensation Expense

$ 372,923

Grant fair value

$ 1,525,525

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Employee [Member] | Employee Stock Option [Member]

STOCK OPTIONS

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

5,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 3.20

Allocated Share-based Compensation Expense

$ 350

$ 350

Grant fair value

$ 14,010

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Employees vest equally on January 24, 2019 [Member]

STOCK OPTIONS

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 23.25

Allocated Share-based Compensation Expense

$ 76,968

Employees vest equally on January 24 2020 [Member]

STOCK OPTIONS

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

23.25

Employees vest equally on January 24 2021 [Member]

STOCK OPTIONS

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 23.25

WARRANTS - Summary of continuit

WARRANTS - Summary of continuity schedule (Details) - $ / shares	6 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Mar. 31, 2019
Number of Warrants, Outstanding and exercisable, Beginning balance	288,517	365,974	365,974
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 40.27	$ 53.19	$ 53.19
Number of Warrants, Expired	(163,483)	0	(204,304)
Weighted-Average Exercise Price, Expired	$ (38.91)		$ (51.85)
Number of Warrants, Outstanding and exercisable, Ending balance	125,034		288,517
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 20.07		$ 40.27
Warrant One [Member]
Number of Warrants, Issued			67,952
Weighted-Average Exercise Price, Issued			$ 55.71
Warrant Two [Member]
Number of Warrants, Issued			6,305
Weighted-Average Exercise Price, Issued			$ 34.50
Warrant Three [Member]
Number of Warrants, Issued			52,590
Weighted-Average Exercise Price, Issued			$ 38.91

WARRANTS - Summary of common sh

WARRANTS - Summary of common share purchase warrants outstanding (Details)	6 Months Ended
	Sep. 30, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	125,034
Warrant One [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price | $ / shares	$ 90
Class of Warrant or Right, Number of Warrants	15,658
Class Of Warrant Or Right Expiry Date	Mar. 31, 2023
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price | $ / shares	$ 37.50
Class of Warrant or Right, Number of Warrants	2,667
Class Of Warrant Or Right Expiry Date	Jun. 27, 2020
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price | $ / shares	$ 9.375
Class of Warrant or Right, Number of Warrants	64,025
Class Of Warrant Or Right Expiry Date	Aug. 14, 2022
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price | $ / shares	$ 9.375
Class of Warrant or Right, Number of Warrants	42,684
Class Of Warrant Or Right Expiry Date	Mar. 31, 2022

WARRANTS - Additional Informati

WARRANTS - Additional Information (Details) - shares	6 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Mar. 31, 2019
WARRANTS
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	2 years 9 months 26 days		1 year 6 months 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations	163,483	0	204,304

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)	Feb. 25, 2015	May 17, 2017	Sep. 30, 2019
Stock Issued During Period, Shares, New Issues	1,753
Stock Issued During Period, Value, New Issues	$ 210,323
Loan received and repaid	$ 241,185
Percentage of Royalty on Sales			1.00%
China JV
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		25.00%
JV Partner
Contribution required from JV Partner within 30 days of joint venture formation		$ 290,000
Contribution required from JV Partner 12 months after joint venture formation		435,000
Contribution required from JV Partner 60 months after joint venture formation		$ 725,000
JV Partner | China JV
Equity Method Investment, Ownership Percentage		75.00%
Former Chief Technology Officer And New Chief Technology Officer [Member]
Stock Transferred To Lenders	2,098
Stock to be Reimbursed to Officers	2,134